SCHEMBL29975892

SCHEMBL29975892

Fc1cccc2ncc(Br)cc12

nearest known ligand 0.51

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PDGFRB P09619 1/20 0.51
PDGFRA P16234 1/20 0.51
BIRC5 O15392 1/20 0.38
PTGES O14684 1/20 0.37
EGFR P00533 5/20 0.36
DYRK1A Q13627 2/20 0.36
DYRK1B Q9Y463 2/20 0.36
PLK4 O00444 1/20 0.36
AURKA O14965 1/20 0.36
JAK2 O60674 1/20 0.36
ROCK2 O75116 1/20 0.36
PRKD3 O94806 1/20 0.36
MAP4K4 O95819 1/20 0.36
PRKCG P05129 1/20 0.36
INSR P06213 1/20 0.36
CDK1 P06493 1/20 0.36
FES P07332 1/20 0.36
IGF1R P08069 1/20 0.36
ROS1 P08922 1/20 0.36
FGFR1 P11362 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL27143938 1.00 PDGFRB (0.51) PDGFRBPDGFRABIRC5PTGESEGFR
SCHEMBL30824494 0.80 PDGFRB (0.54) PDGFRBPDGFRAEGFRMAP4K4MAPK8
SCHEMBL1147558 0.80 BACE1 (0.41) PDGFRABIRC5EGFRDYRK1ADYRK1B
SCHEMBL25245129 0.77 PDGFRB (0.51) PDGFRBPDGFRAEGFRMAP4K4SYK
SCHEMBL21893491 0.77 PDGFRB (0.51) PDGFRBPDGFRAKDM4EGPR3NPC1
SCHEMBL31378734 0.77 DYRK1A (0.36) PDGFRADYRK1ADYRK1BPLK4AURKA
SCHEMBL29976168 0.77 PDGFRB (0.51) PDGFRBPDGFRAEGFRJAK2KDM4E
SCHEMBL23674641 0.77 CYP1A2 (0.39) BIRC5PTGESDYRK1ADYRK1BKDR
SCHEMBL23246961 0.77 MEN1 (0.40) BIRC5PTGESEGFRDYRK1ADYRK1B
SCHEMBL24151481 0.77 KMT2A (0.47) PDGFRABIRC5EGFRDYRK1ADYRK1B

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4547658-A1 WEE1 DEGRADING COMPOUNDS AND USES THEREOF Bristol-Myers Squibb Company (US) 2025-05-07 EP disclosed
WO-2024006881-A1 WEE1 DEGRADING COMPOUNDS AND USES THEREOF BRISTOL-MYERS SQUIBB COMPANY (US) 2024-01-04 WO disclosed
US-11459330-B2 Substituted bicyclic heterocyclic compounds as PRMT5 inhibitors LUPIN LIMITED (IN) 2022-10-04 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11459330-B2 Substituted bicyclic heterocyclic compounds as PRMT5 inhibitors PRMT5, PRMT1, PRMT3 PDGFRB 4299/4885PDGFRA 4271/4885BIRC5 327/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.